We are live on ! Find out more
RPRX icon

Repros Therapeutics
RPRX

Delisted

RPRX was delisted on the 31st of January, 2018.

75 hedge funds and large institutions have $202M invested in Repros Therapeutics in 2014 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 27 increasing their positions, 18 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 18

26% more call options, than puts

Call options by funds: $11.9M | Put options by funds: $9.45M

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

3% less funds holding

Funds holding: 77 → 75 (-2)

11% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 19

10.82% less ownership

Funds ownership: 94.84% → 84.01% (-11%)

26% less capital inflows, than outflows

Capital inflows: $115M | Capital outflows: $156M

Holders
75
Holders Change
-2
Holders Change %
-2.6%
% of All Funds
2.17%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
17
Increased
27
Reduced
18
Closed
19
Calls
$11.9​M
Puts
$9.45​M
Net Calls
+$2.44​M
Net Calls Change
+$4​M

RPRX Hedge Fund Activity: Q3 2014 in Review

75 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Repros Therapeutics (RPRX) for Q3 2014, worth a combined $202M — down 47% from $379M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of RPRX and 17 opened new positions — a net loss of 2 holders — while 18 trimmed existing stakes and 27 added.

The largest buyer was Fidelity Investments, adding an estimated $21.7M. The largest seller was Franklin Resources, exiting entirely with an estimated $45.2M sold.

  • 75 institutional investors held Repros Therapeutics (RPRX) as of Q3 2014, down from 77 in Q2 2014.
  • Funds reported $202M of Repros Therapeutics stock for Q3 2014, down 47% quarter-over-quarter.
  • 17 funds opened new Repros Therapeutics positions in Q3 2014 and 19 closed out, a net change of -2 holders.
  • The largest Repros Therapeutics buyer in Q3 2014 was Fidelity Investments, an estimated $21.7M added.
  • The largest Repros Therapeutics seller in Q3 2014 was Franklin Resources, an estimated $45.2M sold.

Based on aggregated 13F filings for Q3 2014.